Tudor Arvinte, Ph.D., Co-Founder, Therapeomic Inc.; Professor, Department of Pharmaceutics, University of Geneva

Manuel Baca, Ph.D., Principle Scientist, Antibody Discovery & Protein Engineering, MedImmune, Inc.

Patrick Baeuerle, Ph.D., CSO & Senior Vice President, R&D, Micromet

Matthew Baker, Ph.D., CSO, Antitope Ltd.

Stefan Barth, Ph.D., Head, Department of Pharmaceutical Product Development, Fraunhofer IME

Frank Bernhard, Ph.D., Centre for Biomolecular Magnetic Resonance, Institute for Biophysical Chemistry, University of Frankfurt/Main

Imre Berger, Ph.D., Group Leader, Berger Group, EMBL-Grenoble

H. Kaspar Binz, Ph.D., Vice President Technology, Molecular Partners AG

John-Slough Birch, Ph.D., CSO, Biopharmaceuticals, Lonza Group

Juergen Bode, Ph.D., Professor, Medical School Hannover

Isabel Büttel, Ph.D., Scientific Officer, Deputy Head, EU Co-operation Biological Medicinal Products, Paul Ehrlich Institute

Martinus Capelle, Ph.D., Scientist and Project Manager, Therapeomic Inc.; Department of Pharmaceutics, University of Geneva

Justin Caravella, Ph.D., Scientist, Physical Biochemistry, Drug Discovery, Biogen Idec, Inc.

Sofia Costa, Researcher, Biological Engineering, IBBCEB, University of Minho

Emma Cummins, MSc., Senior Scientist, Global Biotherapeutic Technologies, Pfizer

Dominique Desplancq, Ph.D., Research scientist, Biotechnologie des Interactions Moleculaires,
Institut de Recherche de l’Ecole de Biotechnologie de Strasbourg

Thomas Drepper, Ph.D., Institute of Molecular Enzyme Technology (IMET), Heinrich-Heine-Universität Düsseldorf

Doreen M. Floss, Ph.D., Researcher, Institute of Biochemistry, Christian-Albrechts-University

Gert E. Folkers, Ph.D., NMR Spectroscopy Research Group, Bijvoet Center for Biomolecular Research, Utrecht University

Fredrik Y. Frejd, Ph.D., Project Manager, Biotherapeutics, Affibody AB

Arnout Gerritsen, Director Assay & Bioanalytical Science, Genmab

Tariq Ghayur, Ph.D., Senior Principal Scientist & Research Fellow, Biologics, Abbott Bioresearch Center, Inc.

Hervé Ginisty, Ph.D., CSO, GTP Technology

Dragan Grabulovski, Ph.D., Chief Scientific Officer, Covagen, A.G.

Ulla Grauschopf, Ph.D., Sr. Formulation Scientist, Late-Stage Pharmaceutics and Processing Development,
Pharmaceutical & Device Development, Pharma Technical Development Biologics Europe, Hoffmann-La Roche Ltd.

James Groarke, Ph.D., Senior Research Investigator II, Protein Structure, Novartis Institute for Biomedical Research

Claes Gustafsson, Ph.D., Vice President, Marketing and Sales, DNA2.0

Robert Hayes, Ph.D., Venture Leader, Centyrex, a J&J RedScript Venture

Christian Heinis, Ph.D., Laboratory of Therapeutic Proteins and Peptides, Institute of Chemical Sciences and Engineering,
Ecole Polytechnique Fédérale de Lausanne (EPFL)

Josefin-Beate Holz, Chief Medical Officer, Ablynx NV

Kristian H. Jensen, Ph.D., Chief Operating Officer, Pieris AG

Lutz Jermutus, Ph.D., FRSC, Senior Director, Technology, MedImmune

Frank Kensy, Managing Director, m2p-labs GmbH

Peter Kiener, CEO, Zyngenia

Roland Kontermann, Ph.D., Professor, Biomedical Engineering, Institute of Cell Biology & Immunology, University of Stuttgart

Andrew Kosky, Senior Manager, Early Stage Pharmaceutical Development, Genentech, Inc.

Debbie Law, Ph.D., Chief Scientific Officer, Research, Ablynx NV

Jean-Luc Lenormand, Ph.D., HumProTher Laboratory, TheREx-GREPI, TIMC-IMAG Laboratory, University of Joseph Fourier,
UFR de Médecin

Melvyn Little, Ph.D., CSO, Affimed Therapeutics AG

Kenneth Lundstrom, Ph.D., CEO, PanTherapeutics

Matthias Mack, Ph.D., Head, Institute for Technical Microbiology, Mannheim University of Applied Sciences

Soeren Madsen, Ph.D., Group Leader, Bacterial Expression, Bioneer A/S

Stephen Marino, Ph.D., Department of Molecular Membrane Biology, Max Planck Institute of Biophysics

Ana T. Menendez, Ph.D., Senior Director, Biotechnology, Catalent Pharma Solutions

Kendall M. Mohler, Ph.D., Senior Vice President and Chief Scientific Officer, R&D, Trubion Pharmaceuticals, Inc.

Rune Nilsson, Ph.D., Associate Professor, Department of Oncology, Lund University

Raymond Owens, Ph.D., Oxford Protein Production Facility, Welcome Trust Centre for Human Genetics

Arnaud Poterszman, Ph.D., Research Director (CNRS),Structural Biology and Genomics, IGBMC-CERMB

Frank Rosenau, Ph.D., Head, Microbial Expression Technology Group, Institute of Molecular Enzyme Technology,
Heinrich-Heine-University Duesseldorf

Thomas Sandal, Head, Microbial Process Research, GlaxoSmithKline Research & Development

Volker Schellenberger, Ph.D., Vice President, Drug Discovery, Amunix, Inc.

Roelof Schipperus, M.S., Agrotechnology and Food Sciences Group, Wageningen University and Research Center

Arne Skerra, Ph.D., CEO, XL-protein GmbH

Mavanur R. Suresh, Ph.D., Associate Dean of Research, Faculty of Pharmacy and Pharmaceutical Sciences,
University of Alberta, Canada

Robin Thorpe, Ph.D., Head, Biotherapeutics Group, UK National Institute for Biological Standards and Control (NIBSC),
and Rapporteur, EMEA Guideline

Michael Tovey, Ph.D., Director, Research, Viral Oncology, Institute Andre Lwoff

Bernhardt L. Trout, Ph.D., Director, Novartis-MIT Center for Continuous Manufacturing; Director, Concourse; Co-Chair,
Singapore-MIT Alliance, Chemical and Pharmaceutical Engineering; Professor, Department of Chemical Engineering, MIT

David Urech, Ph.D., Head, Research & Development, ESBATech LLC, an ALCON Biomedical Research Unit

Daniel A. Vallera, Ph.D., Lion Scholar and Director, Section on Molecular Cancer Therapeutics, Professor of Therapeutic Radiology,
University of Minnesota Cancer Center

Salvador Ventura, Ph.D., Group Leader, Institut de Biotecnologia Biomedicina, Universitat Autonoma de Barcelona

Bernd Voedisch, Ph.D., Postdoctoral Researcher, Geisse Group, Novartis

Max Woisetschläger, Ph.D., Director, Target Biology, f-star

Zhongren Wu, Research Fellow, Biochemistry, Vitae Pharmaceuticals

Louise Yderland, Group Leader, Proteomics, School of Biotechnology, Royal Institute of Technology, Albanova Universitetscentrum

Jesús Zurdo, Ph.D., Head, Advanced Protein Technologies, Lonza Biologics